The tumor necrosis factor receptor 1 (TNFR1) and the Fas receptor recruit complexes formed by the interactions between RIP kinase, TRADD, FADD and RAIDD -adaptor proteins that contain death domains -which in turn recruit other proteins to initiate signaling [1-5]. To identify proteins associated with the TNF signaling pathway, we performed a yeast twohybrid interaction screen using RIP as bait. We isolated a kinase, RIP3, which shares homology with the kinase domain of RIP and RIP2 (also known as Rick or CARDIAK). RIP3 could be co-immunoprecipitated with RIP, TRAF2 and TNFR1 in mammalian cells. The carboxy-terminal domain of RIP3, like that of RIP, could activate the transcription factor NFκ κB and induce apoptosis when expressed in mammalian cells. Interestingly, this region shares no significant sequence homology to the death domain of RIP, the caspaserecruiting domain (CARD) of RIP2 [6-8] or any other apoptosis-inducing domain. As with RIP and RIP2, the kinase domain of RIP3 was not required for either NFκ κB activation or apoptosis induction. Overexpression of a dominant-negative mutant of RIP3 strongly inhibited the caspase activation but not the NFκ κB activation induced by TNFα α. Therefore, RIP3 appears to function as an intermediary in TNFα α-induced apoptosis. 
expected, many known RIP-binding proteins, including TRAF1, TRAF2, TNFR1, RIP, TRADD and FADD, were cloned; several novel genes were isolated as well. One of the newly identified cDNAs had high sequence homology with RIP, and the full-length cDNA contained a 518 amino acid open-reading frame. Analysis of the amino acid sequence of this protein revealed a kinase domain (between amino acid residues 21 and 287) that had 47% homology to the kinase domain of RIP and 42% homology to that of RIP2; consequently, the protein was designated RIP3 (see Supplementary material published with this paper on the internet). Outside the kinase domain, however, the carboxy-terminal region of RIP3 had no homology to death domains [3] , death effector domains [9] or the CARD region [10] . An approximately 2.1 kb transcript was detected with a cDNA probe specific to RIP3 in both normal human tissue and human tumor RNA blots (see Supplementary material).
To analyze which region of RIP3 was important for interactions with RIP, a series of deletion mutants and a point mutant were engineered ( Figure 1a ). In yeast, the intermediate region (amino acids 82-436) of RIP3 was required for the interaction between RIP and RIP3 ( Figure 1c ). Coimmunoprecipitation analysis was performed to verify the interaction of RIP with RIP3 by co-transfection of hemagglutinin (HA)-tagged RIP with FLAG-tagged full-length and truncated mutants of RIP3 in Phoenix-A (293 T) cells. Figure 1d shows that full-length RIP3, as well as the deletion mutant RIP3(82-518) and the point mutant RIP3(K50D), co-immunoprecipitated with RIP. Interestingly, the RIP3(1-436) deletion mutant had dramatically reduced binding affinity for RIP. No association was detected between RIP and RIP3(1-251), RIP3 or RIP3(287-518). This suggests that the interaction between RIP3 and RIP is mediated by a portion of the kinase domain of RIP3 with additional contribution from the carboxy-terminal domain. To test whether RIP3 was able to bind to endogenous RIP, FLAG-RIP3 was transfected into Phoenix-A cells in the presence and absence of TNFα. Ectopically expressed RIP3 was able to bind to endogenous RIP (Figure 1e ) and TNFα treatment did not significantly affect this binding. In addition, endogenous TNFR1 was co-immunoprecipitated with ectopically expressed RIP3, and endogenous RIP3 was co-immunoprecipitated with ectopically expressed TRAF2 (Figure 1f ). Interaction between TRAF2 and RIP3 was also verified by the yeast two-hybrid system (data not shown). This suggests that RIP3 is part of the TNFR1 signaling complex. RIP3 contains consensus Ser/Thr kinase phosphorylation motifs. An in vitro kinase assay demonstrated that RIP3 was a kinase and was autophosphorylated. The Lys50 residue of the RIP3 kinase domain, homologous to the conserved lysine in RIP that is critical for enzymatic activity and ATP binding [6, 7] , was substituted with aspartic acid. This RIP3(K50D) mutant lacked kinase activity (Figure 1b) , suggesting that this lysine is required for autophosphorylation.
To test whether RIP3 was able to induce cell death, Phoenix-A cells were co-transfected with a eukaryotic RIP3 expression plasmid together with a pGDB control plasmid expressing green fluorescent protein (GFP) to assess transfection efficiency [11] . The GFP-positive RIP3-transfected cells displayed morphological characteristics of apoptosis, including detachment from the plate substrate and resultant 'rounding up' and a condensed and fragmented nucleus [12] (data not shown and see Supplementary material). RIP3-induced apoptosis was also observed in Hela cells (data not shown). Figure 2a shows that approximately 35% of the cells transfected with RIP3 underwent apoptosis, compared with only 2% of the cells transfected with control vector. The carboxyterminal deletion mutant, RIP3(1-436), failed to induce apoptosis. Similarly to RIP [2] and RIP2 [6] , deletion of the RIP3 kinase domain had no effect on its apoptotic activity (data not shown), suggesting that the kinase domain was not required for RIP3-mediated cell death.
Apoptosis induced by TNFα and Fas ligand is controlled by caspase activation [13] . RIP2 has also been reported to induce apoptosis by enhancing caspase activity [7] . To test whether RIP3 activates cellular caspases, a RIP3 expression vector, pYCI-RIP3, was co-transfected into Phoenix-A cells with pGDB. The pGDB plasmid expresses a previously described hybrid protein of GFP and blue fluorescent protein (BFP) linked by a peptide containing the sequence DEVD and is used as a reporter of intracellular caspase activity [11] (Figure 2b ). When caspases 2, 3 or 7 are activated, they specifically cleave appropriately accessible 540 Current Biology, Vol 9 No 10
Figure 1
The association of RIP3 with RIP. All transfections were carried out using the calcium phosphate method. substrates at the DEVD sequence [12] , so GFP and BFP monomers would be released. Western blot analysis using an anti-GFP monoclonal antibody indicated that ectopic expression of RIP3 activated caspases that cleaved the DEVD linker peptide, releasing GFP and BFP monomers (Figure 2b) . A broad-spectrum inhibitor of caspases, termed zVAD-fmk [14] , inhibited the caspase activity triggered by RIP3 expression (data not shown). This result confirmed that cleavage of the chimeric protein was due to caspase activation. RIP3-induced apoptosis could also be inhibited by the caspase inhibitor CrmA (data not shown). Amino-terminal deletion mutants RIP3(82-518) and RIP3(287-518), and RIP3(K50D), were still able to activate caspase activity (Figure 2b) . Deletion of the carboxy-terminal region of RIP3 -constructs RIP3(1-251) and RIP3(1-436) -completely abrogated caspase activation (Figure 2b ). These results again indicate that the kinase activity of RIP3 is not required for activation of caspases and cell death. As the carboxy-terminal domain (amino acids 437-518) of RIP3 is not required for the binding of RIP3 to RIP, this region might bind other proteins involved in unknown pathway(s) that stimulate apoptosis. It is not known whether the carboxy-terminal region of RIP3 is able to bind directly to any known death adaptor or death protease. Additional twohybrid screening using RIP3 as bait is being carried out to find signaling proteins downstream of RIP3.
We also tested whether RIP3 could induce NFκB activation. Phoenix-A cells were harvested for a luciferase reporter assay 24 hours after co-transfection with an NFκB-dependent luciferase reporter construct and pYCI-RIP3. Ectopic expression of RIP3 alone induced NFκB activation approximately sevenfold (Figure 2c ). The NFκB activation could be inhibited by co-transfection of an IκB dominant-negative mutant (data not shown). The carboxyterminal region of RIP3 was essential for NFκB activation, as RIP3(1-251) and RIP3(1-436) were not able to activate NFκB. Interestingly, RIP3(K50D), RIP3(82-518) and RIP3(287-518) induced higher luciferase activity than fulllength RIP3 (Figure 2c ). This suggests that the kinase domain of RIP3 is not required for the NFκB activation. In contrast, RIP3 had no noticeable effect on activation pathways mediated by the transcription factor AP-1 (data not shown).
Although RIP3 associates with RIP and TRAF2 and activates apoptosis and NFκB, its function in the TNFα signaling pathway needs to be dissected. In overexpression experiments, RIP3(1-436) inhibited TNFα-induced caspase activation (Figure 3b ) but not TNFα-induced NFκB activation (data not shown), suggesting that RIP3 is involved in the TNFα-mediated apoptosis pathway. These results imply that without the carboxy-terminal domain (amino acids 437-518), RIP3 either competes with or fails to recruit other proteins of the TNF signaling complex required for the activation of caspases. In separate experiments, RIP3(1-436) was able to downregulate RIP-mediated apoptosis activation: whereas Brief Communication 541 The carboxyterminal region of RIP3 is required for NFκB activation. NFκB reporter activity was determined by a luciferase assay after transiently co-transfecting Phoenix-A cells with empty vector or the indicated RIP3 expression plasmids (3 µg), an NFκB-dependent luciferase reporter plasmid (1 µg), and a Renilla luciferase expression plasmid (0.13 µg). The calcium phosphate precipitation method was used for transfection. The level of expressed tagged proteins was monitored by western blot analysis (data not shown).
co-transfection of full-length RIP3 (3 µg) with RIP (0.1 µg) resulted in greater caspase activity than with RIP alone (Figure 3a) , RIP3(1-436) significantly reduced RIP-induced caspase activity (Figure 3a) . In contrast, although RIP3 alone was able to activate NFκB, co-transfection of RIP (0.3 µg) and full-length RIP3 (3 µg) in Phoenix-A cells did not have any synergistic effect on NFκB activation. When RIP3(1-436) was co-transfected with RIP, the RIP-mediated NFκB activation was only slightly reduced (see Supplementary material). Another RIP3 mutant (amino acids 287-518) was still able to activate caspases and NFκB, even though it did not bind RIP (data not shown).
In summary, we have demonstrated that RIP3 is a novel kinase associated with the TNFα signaling complex. RIP3 binds to RIP and TRAF2 in both yeast and mammalian cells and co-immunoprecipitates with TNFR1. Although RIP is an essential player in TNFα-induced NFκB activation [15] , and RIP3 was cloned by binding to RIP, the function of RIP3 might not rely solely on its binding to RIP. A dominant-negative form of RIP3 can inhibit TNFα-induced caspase activation without affecting TNFα-induced NFκB activation, suggesting that RIP3 might be involved in TNFα-induced apoptosis. It is possible that RIP3 and RIP are therefore involved in two different areas of TNFα signaling: apoptosis and NFκB activation, respectively. The precise role of RIP3 in TNFα signaling may be answered in the future by 'knock-out' experiments.
Supplementary material
Figures showing RIP3 expression in human tissues, RIP kinase sequences, Phoenix-A cells undergoing apoptosis after transfection with RIP3, and the partial reduction of RIP-mediated NFκB activation by RIP3(1-436) are published with this paper on the internet. 
